Selection of blockbuster announcements

1 、$Ganfeng Lithium (01772.HK) $Net profit in 2021 was 5.175 billion yuan, an increase of 405.03% over the same period last year

Ganfeng Lithium announced that KuaiBao, the company's performance in 2021, realized operating income of 11.162 billion yuan, an increase of 102.07% over the same period last year; net profit belonging to shareholders of listed companies was 5.175 billion yuan, up 405.03% over the same period last year; and basic earnings per share was 3.66 yuan, an increase of 363.29% over the same period last year.

In addition, according to the company's preliminary accounting, from January 2022 to February 2022, the company achieved an operating income of about 3.6 billion yuan, an increase of about 260% over the same period last year, and a net profit of about 1.4 billion yuan belonging to shareholders of listed companies, an increase of about 300% over the same period last year.

2 、$China Tobacco Hong Kong (06055.HK) $Net profit in 2021 soared by 562.29% to HK $703 million, with a final interest rate of HK17 cents

China Tobacco Hong Kong announced that for the year ended December 31, 2021, the company's revenue was HK $8.064 billion, an increase of 131.42% over the same period last year; the profit attributable to equity holders was HK $703 million, an increase of 562.29% over the same period last year; and earnings per share was HK $1.02. It is proposed to pay a final dividend of HK17 cents per share.

3 、$Fuhong Hanlin (02696.HK) $The phase 1 clinical study of ACE2-Fc receptor fusion protein HLX71 (used in the treatment of COVID-19) showed that it was safe and well tolerated.

Fuhong Hanlin announced that the company's independently developed ACE2-Fc receptor fusion protein HLX71 (HLX71) has recently completed a phase 1 clinical trial, which has shown good safety and tolerance in a phase 1 clinical study in healthy adult subjects.

4 、$Li Auto Inc.-W (02015.HK) $Shares of the company are included in the Shenzhen-Hong Kong Stock Connect

On March 14, 2022 (US Eastern time), Li Auto Inc. ("Li Auto Inc." or the "Company"), the innovator of China's new energy vehicle market, (NASDAQ: LI; Hong Kong Exchanges and Clearing: 2015) announced that, according to the announcement of the Shenzhen Stock Exchange, the company's Class A common shares listed on the Shenzhen Stock Exchange will be included in the Shenzhen-Hong Kong Stock Connect on 14 March 2022.

• Important matters

Sino Biopharmaceutical (01177): luraceone Hydrochloride tablets obtained Drug Registration Certificate

Xianjian Technology (01302): the first confirmed clinical case of IBS ®absorbable drug eluting coronary stent system in China was successfully enrolled.

Cornerstone Pharmaceutical-B (02616): Pujihua ®is approved for the treatment of advanced or metastatic RET mutated thyroid medullary carcinoma and RET fusion positive thyroid carcinoma in China.

Fu Hong Hanlin (02696): the results of phase 1 clinical study in the treatment of COVID-19 HLX71 showed that it was safe and well tolerated.

China Antibody-B _ (03681) SM17 New Drug Research Application approved by FDA

Lizhu Medicine (01513): clarithromycin tablets produced by Lizhu Pharmaceutical Factory were evaluated by the consistency of the quality and efficacy of generic drugs.

Rongchang Biological-B (09995) plans to issue 54.4263 million new shares to be listed by Science and Technology Innovation Board

• Financial report data

Or turn losses into profits, Sima Ophthalmology (03309) expects annual profits attributable to shareholders of HK $15 million to HK $25 million

Cathay Pacific (00293) carried 31200 passengers in February, an increase of 47.9% over the same period last year.

China Renaissance Holdings Ltd. (01911) expects the profit attributable to shareholders to be 1.624 billion yuan in 2021, an increase of about 56.5% over the same period last year.

Zhongan Online (06060) the total premium income of the original insurance increased by 8.34% to 3.353 billion yuan in the first two months compared with the same period last year.

PRADA S.p.A. (01913) made a net profit of 294 million euros in 2021.

The operating profit of Yum China-S (09987) in the first two months is about 20% lower than that of the same period last year. It is estimated that the operating profit in the first quarter is about 165 million to 200 million US dollars.

• Listing of new shares

Clear Healthcare (01406): the stable price period ends and the over-allotment option fails.

• Merger and acquisition and sale

Cang Hai Holdings (02017.HK) plans to transfer 55% stake in Ningbo Hongyuan Construction

• Repurchase cancellation

Standard Chartered PLC (02888.HK) spent 15.294 million pounds to buy back 3.132 million shares on March 11.

HSBC Holdings PLC (00005.HK) spent 5.116 million pounds to buy back 1.067 million shares on March 11.

IMAX CHINA (01970.HK) spent HK $4.4177 million to buy back 450000 shares on March 14.

00182.HK spent HK $2.6452 million to buy back 3.89 million shares on March 14.

00014.HK spent HK $2.13 million to buy back 100000 shares on March 14.

• Equity incentive

00303.HK: granting a total of 1 million share options to three executive directors and two employees

• Bond bill

Shenwan Hongyuan (06806): Shenwan Hongyuan Securities intends to apply for the issue of 20 billion yuan of sustainable subordinated bonds